# Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

> **NCT02573233** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 42 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dupilumab SAR231893/REGN668
- **DRUG:** fluticasone propionate and salmeterol
- **DRUG:** budesonide and formoterol
- **DRUG:** mometasone furoate and formoterol

## Key facts

- **NCT ID:** NCT02573233
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-27
- **Primary completion:** 2018-01-03
- **Final completion:** 2018-01-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573233, "Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02573233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*